HealthQuill Gilead Sciences
US regulator, the FDA has approved Gilead Sciences, Inc.'s supplemental new drug application for treating chronic hepatitis B virus in paediatric patients six years of age and older.
Drugs Health Pharma

FDA nod for Gilead to expand hepatitis drug to six years or older patients

HQ Team March 28, 2024: US regulator, the FDA has approved Gilead Sciences, Inc.’s supplemental new drug application for treating chronic hepatitis B.

Read More
Gilead Sciences, Inc., announced it has discontinued trials on a drug to treat blood cancer after the US regulatory body placed the experiments on full clinical hold, according to a company statement.
Drugs Health Pharma

Gilead Sciences puts last-stage blood cancer trials on hold after FDA order

HQ Team February 8, 2024: Gilead Sciences, Inc., announced it has discontinued trials on a drug to treat blood cancer after the US.

Read More
The USFDA is probing cancer therapies of Gilead Sciences, Johnson & Johnson and Novartis following reports of malignancies in patients who received treatment.
Drugs Health Pharma

FDA probing T cell cancer therapies of Gilead Sciences, Novartis, J & J

HQ Team November 29, 2023: The USFDA is probing cancer therapies of Gilead Sciences, Johnson & Johnson and Novartis following reports of malignancies.

Read More
The number of people affected by neglected tropical diseases (NTDs) has fallen by 80 million between 2020 and 2021, a WHO report stated.
Drugs Health Pharma

NTD incidence fall by 80 million people, WHO chief calls for funds

The number of people affected by neglected tropical diseases (NTDs) has fallen by 80 million between 2020 and 2021, a WHO report stated.

Read More
X